Publications by authors named "Cory L Gamble"
Purpose: The purpose of this study was to evaluate patient, prescriber, and dose characteristics and evaluate changes in glycated hemoglobin (HbA) for patients prescribed once weekly semaglutide for diabetes (OW sema T2D).
Methods: This study was a retrospective claims-based study using the Optum Research Database. The sample included adult patients who had at least one claim for OW sema T2D between Jan 1, 2018, and Dec 31, 2019, were continuously enrolled in the health plan and had a diagnosis of type 2 diabetes (T2DM) during the pre-index or post-index periods.
Background: The efficacy of once-weekly (OW) glucagon-like peptide-1 receptor agonists (GLP-1RAs) has been established in several trials in people with type 2 diabetes mellitus (T2DM); however, real-world evidence on their effectiveness is limited. This study evaluated the effectiveness of OW GLP-1RA regarding glycemic and weight outcomes, and relative to DPP-4i in a comparator analysis.
Methods: This observational cohort study evaluated glycated hemoglobin (HbA) and weight outcomes in people with T2DM with two or more prescription claims for the same OW GLP-1RA using a pre-post study design (including for a semaglutide OW T2DM subgroup, hereafter referred to as semaglutide).
Article Synopsis
- Cardiovascular disease is a major health issue for people with type 2 diabetes (T2D), prompting an analysis of how often proven therapies are used to lower cardiovascular risk over time in the U.S.
- Data from a large diabetes registry showed an increase in prescriptions for SGLT2 inhibitors and GLP-1 receptor agonists from 2013 to 2019, yet fewer patients with high-risk conditions (like heart failure or chronic kidney disease) were receiving these medications compared to those without these comorbidities.
- The findings highlight a treatment-risk paradox, suggesting that while the use of certain medications has improved, there is still a gap in their use among those who would benefit the most, indicating a need for better education on
Introduction: Improving real-world medication adherence to injectable antihyperglycemics in type 2 diabetes mellitus (T2DM) is a clinical challenge. Quantification of the level of adherence required to achieve a minimal clinically important difference (MCID) in glycemic control would assist in meeting this goal. The study objective was to review the literature regarding the relationships of medication adherence and persistence with health outcomes in adult T2DM patients using injectable antihyperglycemics.
View Article and Find Full Text PDF